Top Pharmaceutical Companies in Chicago, IL (79)
Our mission is to improve health outcomes through behavior change at the point of care and beyond. Every day, people make choices that shape their health, and at PatientPoint, we strive to support those decisions with the right information delivered at the right time. We're proud to power the largest network of digital devices in doctor's offices across the country —...
PatientPoint's Top Stability & Growth Strengths
Strong Revenue Growth: Company disclosures point to multi‑year top‑line expansion, with independent credit commentary anticipating continued gains. The scale of the installed healthcare network reinforces commercial traction over time.
Market Expansion: Recent launches of a Consumer Health Network and programmatic advertising capabilities extend reach beyond traditional pharmaceutical clients and open new buying channels. These moves indicate active growth into adjacent advertiser categories within healthcare settings.
Investor Backing & Capital Strength: A definitive agreement to be acquired by a global private‑equity firm underscores institutional confidence and adds resources to accelerate network growth and product innovation. The transaction highlights access to capital to support scaling.
Energy CX is a family-founded energy broker redefining how businesses buy energy. Powered by ABEL™, a proprietary platform, the company uses math-based trading methodologies to help customers treat energy like an investment, not a line item. Energy CX replaces fragmented tools and legacy broker models with a centralized, technology-led approach—reducing risk, controlling spend, and bringing clarity to complex energy markets....
Energy CX's Top Stability & Growth Strengths
Strong Revenue Growth: Evidence points to strong multi‑year revenue expansion, including three consecutive Inc. 5000 appearances with an improving rank. Additional signals include notable 2024 revenue growth and a Crain’s Chicago Business Fast 50 placement reflecting five-year performance.
Market Expansion: Operations span more than 20 states and a New York City office opened in October 2026 to deepen Northeast coverage. The company reports serving over 1,000 customers and managing more than 2 billion square feet, indicating widening commercial reach.
Strong Hiring & Retention: Headcount rose from 68 to 108 during 2025, with current materials citing a team of 150+ people. Office expansions and ongoing hiring across functions suggest organizational scaling to support growth.
Fresenius is a global healthcare company headquartered in Germany, dedicated to saving and improving human lives through affordable and innovative healthcare products and high-quality clinical care. The company focuses on three key therapy platforms: (Bio)Pharma, MedTech, and Care Provision, providing system-critical products and services for the treatment of critically and chronically ill patients worldwide.
ProcDNA is a global analytics and technology consulting firm dedicated to delivering exceptional commercial analytics and technology solutions to the life sciences and healthcare sectors. Established in 2020, the company leverages a blend of design thinking, advanced data analytics, and AI to solve complex business challenges, transform data into commercial intelligence, and help pharmaceutical and biotechnology organizations achieve their goals...
KMR is a global leader in benchmarking, analytics, and performance management, with an exclusive focus on biopharmaceutical R&D.
Mallinckrodt Pharmaceuticals plc is a global specialty pharmaceutical company with over 150 years of experience. Historically a manufacturer of specialty pharmaceuticals, generic drugs, and imaging agents, the company transitioned in November 2025 to be known as Keenova Therapeutics. It now focuses on developing, manufacturing, and commercializing branded therapeutics designed to help patients with rare or unaddressed conditions live healthier and...
Carlson Laboratories is a family-owned and operated company founded in 1965. They specialize in producing high-quality nutritional supplements, including award-winning Norwegian fish oils, vitamins, and minerals. Committed to purity, potency, and scientific integrity, the company focuses on promoting health and wellness for families globally through its science-based dietary products.
Providing patients with comprehensive and compassionate care since 1987, Orsini is the leading, independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions. Orsini’s high-touch care model centers around compassionate, therapy-specific care teams who provide personalized care to patients based on their specific condition and treatment. The company’s comprehensive solutions include medication adherence programs, data analytics, customized manufacturer...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
ProPharma's Top Stability & Growth Strengths
Market Expansion: Feedback suggests the company is broadening its global footprint, including opening a new office in Hyderabad and expanding across Central and Eastern Europe via acquisitions. These moves indicate a focus on scaling operations and accessing new markets.
Strategic Partnerships: Feedback suggests targeted acquisitions such as Clinres Farmacija and Digital Lab Consulting are used to enhance capabilities and geographic reach. These integrations appear to strengthen end-to-end service coverage across regulatory, clinical, and R&D functions.
Strong Brand Reputation: Feedback suggests multiple industry awards and recognitions, including CPHI and CRO Leadership distinctions, bolster standing as a top-tier provider. External analyst mentions, such as Everest Group’s PEAK Matrix designation, reinforce credibility.
Marathon Petroleum Corporation (MPC) is a leading, integrated, downstream energy company headquartered in Findlay, Ohio. The company operates the nation's largest refining system. MPC's marketing system includes branded locations across the United States, including Marathon brand retail outlets. MPC also owns the general partner and majority limited partner interest in MPLX LP, a midstream company that owns and operates gathering,...
Marathon Petroleum Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Quarterly revenue showed sharp momentum, with Q2 reaching approximately $52.3 billion versus roughly $34.1 billion a year earlier, while trailing 12-month trends point toward robust expansion as demand and utilization rebound.
Profitability: Earnings and profitability exceeded expectations, including Q2 EPS of $17.73 and full-year 2025 net income of $4.0 billion with adjusted EBITDA of $12.0 billion, supported by high crude capacity utilization near 94–95%.
Strategic Partnerships: Midstream expansion via MPLX underpins structural growth, with a $2.4 billion organic growth capital plan focused on natural gas and NGL infrastructure and expected distribution growth supporting dividends and capital spending.
Meitheal Pharmaceuticals is an agile biopharmaceutical company dedicated to simplifying access to life-changing medicine. Based in Chicago, Illinois, it manufactures innovative biopharmaceutical products, with a focus on generic injectable pharmaceuticals and biosimilars across various therapeutic areas, including oncology and metabolic diseases.
At Astellas, we strive to be a cutting-edge, value-driven life science innovator. This means working at the forefront of healthcare change to turn innovative science into the best outcomes for patients. Operating in approximately 70 countries with more than 14,000 employees, we are relentless in our pursuit of scientific progress and in tackling unmet medical needs. Visit our Global Astellas...
Astellas Pharma's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record level in FY2024 with double‑digit year‑over‑year growth, and management raised FY2025 guidance after continued momentum through the first nine months. Company updates attribute this to strong contributions from “Strategic Brands” including PADCEV, VYLOY, VEOZAH, IZERVAY and sustained XTANDI demand.
Profitability: Core operating profit increased markedly faster than sales in FY2025 year‑to‑date, reflecting margin expansion. Management links improvement to mix benefits from strategic brands and cost programs such as the Sustainable Margin Transformation initiative.
Strong Market Position & Advantage: Astellas demonstrates category leadership in niches—XTANDI in prostate cancer and PADCEV + Keytruda setting a new first‑line standard in advanced urothelial cancer with later perioperative expansion. First‑in‑class positions in CLDN18.2 gastric cancer (VYLOY) and non‑hormonal menopause therapy (VEOZAH) further strengthen its competitive footing.
Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies....
Frontage Laboratories, Inc's Top Stability & Growth Strengths
Market Expansion: Recent announcements describe expansion of early‑phase clinical capabilities in 2026 alongside new and enlarged sites in Exton, Pennsylvania and Europe, indicating broader geographic reach and capacity. Acquisitions and a rising backlog/future contracted revenue further point to continuing expansion into additional markets and regions.
Product Line Growth: New GMP CRDMO capacity came online with a 46,300‑sq‑ft facility opened in 2025 and fully validated by late 2025, adding nine GMP suites and related labs. The 2026 acquisition of a CAP‑accredited central lab in China and added early‑phase clinical capabilities broaden the service portfolio.
Strong Revenue Growth: Recent interim results show first‑half 2026 revenue up 17.1% year over year with net profit more than doubling, signaling a rebound from prior softness. Purchase orders/backlog also increased versus prior periods, supporting near‑term top‑line momentum.
rVibe helps pharmaceutical companies sell more drugs and reduce training expense by providing live online learning and virtual training software and services.After assessing an organization's virtual learning maturity using rVibe's Virtual Maturity Model, we help our business partners develop and apply a robust, repeatable and effective virtual learning model using a variety of technologies, processes and equipment. Our Persistant Learning...
Vantive is a standalone vital organ therapy company dedicated to extending lives and expanding possibilities for patients and care teams globally. Building on a 70-year legacy in kidney care, Vantive provides innovative therapies, digital solutions, and advanced services for dialysis and critical care. The company operates in over 100 countries, focusing on improving outcomes for millions of patients through its...
A Safe Haven LLC is a non-profit social enterprise providing comprehensive behavioral health services, including psychiatry and substance use treatment. In partnership with the A Safe Haven Foundation, it offers individualized case management, education, job training, and supportive housing solutions to help individuals in crisis transition from homelessness to self-sufficiency. The organization also operates a licensed community pharmacy.
We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.
Xeris Pharmaceuticals's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is portrayed as rising sharply year over year, with multiple references to double‑digit quarterly increases and a step-up from 2024 to 2025. Guidance for 2026 indicates continued expansion, reinforcing a trajectory of sustained top-line gains.
Profitability: Statements indicate a transition toward financial sustainability, including reports of positive net income and Adjusted EBITDA in 2025. This suggests improving earnings quality alongside revenue growth.
Strong Market Position & Advantage: Observations highlight a specialized leadership in nonaqueous, ready-to-use injectable formulations through XeriSol and XeriJect. Commercial traction for Gvoke within its niche supports a defensible position in targeted segments.
JDP Therapeutics develops small molecule therapeutics for the treatment of life threatening diseases with unmet medical needs.
Amerita, Inc. is a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. This market is expanding rapidly and is driven by increasing healthcare costs that are moving patients into the most cost-effective delivery settings, a growing bio-pharmaceutical pipeline of
